MCRB - Seres Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
237.57M
Enterprise Value 3
162.09M
Trailing P/E
N/A
Forward P/E 1
-2.84
PEG Ratio (5 yr expected) 1
0.02
Price/Sales (ttm)
6.01
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
4.10
Enterprise Value/EBITDA 6
-2.32

Trading Information

Stock Price History

Beta (3Y Monthly) 2.51
52-Week Change 3-49.37%
S&P500 52-Week Change 312.80%
52 Week High 39.0000
52 Week Low 32.0200
50-Day Moving Average 33.5844
200-Day Moving Average 33.8460

Share Statistics

Avg Vol (3 month) 3337.6k
Avg Vol (10 day) 3182.51k
Shares Outstanding 569.91M
Float 40.94M
% Held by Insiders 117.50%
% Held by Institutions 177.62%
Shares Short (Sep 30, 2019) 43.35M
Short Ratio (Sep 30, 2019) 47.51
Short % of Float (Sep 30, 2019) 430.46%
Short % of Shares Outstanding (Sep 30, 2019) 44.80%
Shares Short (prior month Aug 30, 2019) 42.31M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -198.12%
Operating Margin (ttm)-197.01%

Management Effectiveness

Return on Assets (ttm)-34.89%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)39.54M
Revenue Per Share (ttm)0.94
Quarterly Revenue Growth (yoy)171.70%
Gross Profit (ttm)-67.69M
EBITDA -70M
Net Income Avi to Common (ttm)-78.33M
Diluted EPS (ttm)-1.8660
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)102.23M
Total Cash Per Share (mrq)1.46
Total Debt (mrq)22.42M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)2.53
Book Value Per Share (mrq)-0.26

Cash Flow Statement

Operating Cash Flow (ttm)-54.6M
Levered Free Cash Flow (ttm)-28.92M